About
Vironexis was founded to translate the groundbreaking AAV-delivered T-cell immunotherapy technology invented by our co-founder Timothy Cripe, M.D., Ph.D. into a new modality that could redefine the future of cancer treatment.
T-cell immunotherapy is unquestionably a powerful, proven approach to ignite powerful tumor cell killing.
Based on our extensive experience pioneering AAV gene therapy companies and products, we firmly believe AAV gene therapy provides the technological advantages needed to solve many of the drawbacks and shortcomings associated with existing T-cell immunotherapies like CAR-T and bispecific antibodies.
Our TransJoin™ AAV Gene Therapy Platform has the potential to deliver T-cell immunotherapy treatments that are safer, and more effective, durable, scalable, and practical for patients. Our goal: help more cancer patients achieve better outcomes through T-cell-mediated cancer killing.
Productivity &
Unprecedented Progress
Since our founding in 2021, we have made remarkable progress building our TransJoin™ AAV Gene Therapy Platform and leveraging it to build a pipeline of more than 10 product candidates.
Key Milestones To Date:
INVESTORS
